Publications by authors named "Orla Gray"

Claim this Profile
M
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Orla Gray

J Neurol Neurosurg Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.
Ruth Dobson, Tarunya Arun, James Varley, Jeremy Chataway, Wallace Brownlee, Orla Gray

Mult Scler Relat Disord· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, Sara Eichau, Stella Hughes, Orla Gray

Mult Scler· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.
Ashkan Pirmani, Edward De Brouwer, Ádám Arany, Martijn Oldenhof, Antoine Passemiers, Orla Gray

NPJ Digit Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Orla Gray

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, Pascal Benkert, Sandra Vukusic, Orla Gray

J Neurol Neurosurg Psychiatry· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
Cathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, Vincent Van Pesch, Francesco Patti, Orla Gray

J Neurol Neurosurg Psychiatry· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Anoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, Tim Spelman, Louise Rath, Orla Gray

J Neurol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world persistence of multiple sclerosis disease-modifying therapies.
Emma C Tallantyre, Ruth Dobson, Joseph L J Froud, Frederika A St John, Valerie M Anderson, Orla M Gray

Eur J Neurol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.
Edward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, Pieter Dewulf, Dimitrios Iliadis, Orla Gray

PLOS Digit Health· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Big Multiple Sclerosis Data network: an international registry research network.
Anna Glaser, Helmut Butzkueven, Anneke van der Walt, Orla Gray, Tim Spelman

J Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase.
Tim Spelman, Sara Eichau, Raed Alroughani, Serkan Ozakbas, Samia J Khoury, Orla Gray

Mult Scler J Exp Transl Clin· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Ying Li, Alice Saul, Bruce Taylor, Anne-Louise Ponsonby, Steve Simpson-Yap, Orla Gray

J Neurol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Ibrahima Diouf, Charles B Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Orla Gray

J Neurol Neurosurg Psychiatry· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpas, Marina M Sánchez, Orla Gray

Brain· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B Malpas, Sifat Sharmin, Orla Gray

JAMA Neurol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Orla Gray

Mult Scler· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Ibrahima Diouf, Charles B Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Orla Gray

Eur J Neurol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Orla Gray

Mult Scler· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Neurology Advanced Referral Management System (NARMS) Reduces Face-to-Face Consultations By Over Sixty Percent.
John McConville, Annemarie Hunter, Ailsa Fulton, Orla Gray, Andrew Kerr

Ulster Med J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Sifat Sharmin, Francesca Bovis, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Orla Gray

Eur J Neurol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
Marianna Vitkova, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Orla Gray

Neurology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MSBase pregnancy, neonatal outcomes, and women's health registry.
Vilija G Jokubaitis, Olga Skibina, Raed Alroughani, Ayse Altintas, Helmut Butzkueven, Orla Gray

Ther Adv Neurol Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Orla Gray

Neurology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Adam Fambiatos, Vilija Jokubaitis, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Orla Gray

Mult Scler· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis